(Alliance News) - BATM Advanced Communications Ltd on Tuesday said its in-vitro testing subsidiary had received its first commercial meningitis testing order.
Shares in BATM were up 5.7% at 40.70 pence in London in morning trading.
Ador Diagnostics, BATM's unit focused on developing and marketing in-vitro molecular diagnostics products, received its first commercial order from what it described as "the leading Italian distributor of molecular biology and genomics products". The name of this distributor was not disclosed.
Ador is to deliver its NATlab reader and cartridges for identifying meningitis in the second half of 2020. NATlab is Ador's molecular diagnostics platform which allows for rapid diagnosis of bacteria, fungal, or viral infections using DNA sampling.
BATM Chief Executive Zvi Marom said: "We are delighted that Ador has received the first commercial order for the NATlab system, which is an important milestone. Meningitis is a leading infectious cause of childhood death - and speed of identification and treatment is vital. We are proud that our rapid sample-to-answer solution will help medical practitioners to quickly and efficiently diagnose the specific infection and administer the required treatment.
Marom added: "Ador is also working alongside prominent academic and research institutions, including in the UK, to develop more panels for the identification of further diseases. We look forward to reporting on Ador's progress."
By Anna Farley; annafarley@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
Batm Advanced (BVC)